<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00469209</url>
  </required_header>
  <id_info>
    <org_study_id>2005-0893</org_study_id>
    <nct_id>NCT00469209</nct_id>
  </id_info>
  <brief_title>Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients</brief_title>
  <official_title>Phase I/II Study of the Combination of Bortezomib With Arsenic Trioxide, Ascorbic Acid and High-Dose Melphalan for Patients With Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cephalon</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objectives:&#xD;
&#xD;
        1. To evaluate the toxicity and safety of a combination of bortezomib with arsenic&#xD;
           trioxide, ascorbic acid and high-dose melphalan in patients with multiple myeloma&#xD;
&#xD;
        2. To evaluate the efficacy of a combination of bortezomib with arsenic trioxide, ascorbic&#xD;
           acid and high-dose melphalan in patients with multiple myeloma&#xD;
&#xD;
        3. To determine the effects of bortezomib on melphalan pharmacokinetics&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Melphalan is designed to damage the DNA of cells, which may cause cancer cells to die.&#xD;
      High-dose melphalan is considered the standard of care for multiple myeloma. Bortezomib is&#xD;
      designed to block a protein that plays a role in cell function and growth, which may cause&#xD;
      cancer cells to die. Arsenic trioxide may cause cancer cells to die, and researchers want to&#xD;
      find out if arsenic trioxide helps melphalan in killing cancer cells. Vitamin C makes arsenic&#xD;
      trioxide more available inside the cancer cells, and researchers want to learn if Vitamin C&#xD;
      makes arsenic trioxide more effective.&#xD;
&#xD;
      Before you can start treatment on this study, you will have &quot;screening tests.&quot; These tests&#xD;
      will help the doctor decide if you are eligible to take part in this study. You will have a&#xD;
      physical exam, including measurement of vital signs (blood pressure, heart rate, temperature,&#xD;
      and breathing rate). Your complete medical history will be recorded. You will have a dental&#xD;
      exam to check for any infected teeth or gums that may flare up after chemotherapy.&#xD;
&#xD;
      You will have a bone marrow aspirate and biopsy. To collect a bone marrow aspirate/biopsy, an&#xD;
      area of the hip or chest bone is numbed with anesthetic, and a small amount of bone marrow is&#xD;
      withdrawn through a large needle. Cytogenetic tests will be performed on the aspirate sample&#xD;
      to look for any genetic abnormalities in your DNA. You will have x-rays of your bones taken.&#xD;
      The study doctor will look at the x-rays to see if there are any myeloma-related bone&#xD;
      changes. You will also have a chest x-ray.&#xD;
&#xD;
      You will have blood (about 2 tablespoons) and urine collected for routine tests. You will&#xD;
      have a pulmonary function test, to check if your lungs are strong enough for high-dose&#xD;
      chemotherapy. You will have an electrocardiogram (ECG -- a test that measures the electrical&#xD;
      activity of the heart). You will also have a MUGA scan to evaluate the function of your&#xD;
      heart. Women who are able to have children must have a negative blood pregnancy test. The&#xD;
      blood will be drawn as part of the 2 tablespoons drawn at screening.&#xD;
&#xD;
      If you are found to be eligible to take part in this study, you will be randomly assigned (as&#xD;
      in the toss of dice) to one of 3 treatment groups. There is an equal chance of being assigned&#xD;
      to any of the 3 groups. All 3 groups will receive melphalan, arsenic trioxide, and Vitamin C.&#xD;
      The second and third groups will also receive bortezomib, but at different dose levels. The&#xD;
      first 3 participants assigned to receive bortezomib on this study will receive the lower of 2&#xD;
      bortezomib dose levels.&#xD;
&#xD;
      You will receive arsenic trioxide through a needle in a vein over 2 hours, once a day for 7&#xD;
      days (Days -9 to -3). At the same time, you will receive Vitamin C once a day through the&#xD;
      vein for 7 days. After you receive the arsenic trioxide on Days -4 and -3, you will receive&#xD;
      melphalan through the vein over 30 minutes.&#xD;
&#xD;
      If you are in Group 2 or 3, you will receive bortezomib by an intravenous (IV) push on Days&#xD;
      -9, -6, and -3. An IV push takes a short period of time (less than 1 minute).&#xD;
&#xD;
      You will receive standard inpatient and outpatient stem cell transplant care and testing. You&#xD;
      will have to sign a separate consent form that describes the transplant procedure and its&#xD;
      risks. Your stem cells will be reinfused 2 days after the last dose of melphalan. To check&#xD;
      for any side effects, you will have an ECG performed 14 days after the transplant.&#xD;
&#xD;
      If intolerable side effects from the chemotherapy occur or there is sign of disease after the&#xD;
      transplant, you will be taken off study. If you have already received melphalan and side&#xD;
      effects occur, then the transplant will happen. However, if intolerable side effects develop&#xD;
      before melphalan, then you may be taken off study without having the transplant. If you are&#xD;
      taken off study early, you still may need to return for routine post-transplant follow-up&#xD;
      visits, if your transplant physician decides it is necessary.&#xD;
&#xD;
      If there is no sign of disease after the transplant, you will have routine follow-up visits.&#xD;
      Blood (about 2 tablespoons) will be drawn for routine tests at least once a week during the&#xD;
      first month after the transplant, and then once every month for the next 3 months after that.&#xD;
      At about 3, 6, and 12 months after the transplant, you will have bone marrow biopsies and&#xD;
      aspirates performed to check the status of the disease. You will have blood (about 2&#xD;
      tablespoons) and urine collected for routine tests. At 12 months after the transplant, you&#xD;
      will have x-rays of your bones taken.&#xD;
&#xD;
      One (1) year after the transplant, your participation in this study will be over.&#xD;
&#xD;
      This is an investigational study. Bortezomib, arsenic trioxide, and melphalan are&#xD;
      commercially available and FDA-approved for use in patients with myeloma. However, their use&#xD;
      in combination with Vitamin C (also commercially available) is investigational. Up to 60&#xD;
      patients will take part in this study. All will be enrolled at M. D. Anderson.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Reaching Complete Response (CR)</measure>
    <time_frame>Baseline through Day 180, with assessments at Day 90 and Day 180</time_frame>
    <description>Number of participants with CR at Day 180 who had maintained CR for at minimum of 4 weeks, and who had: No monoclonal protein in urine/serum when analyzed by immunofixation electrophoresis; bone marrow normal by morphological examination with &lt;5% plasma cells, &lt;1% aneuploid light chain restricted population by flow cytometry for DNA/cIg; and, while healing of bony lesion is not required, no new lytic lesion should appear. Further compression fracture of spine not considered progressive disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Toxicity</measure>
    <time_frame>Baseline to event occurence (assessed weekly first 30 days)</time_frame>
    <description>The time to patient toxicity of drug combination bortezomib with arsenic trioxide, ascorbic acid and high-dose melphalan defined in days from baseline measure to occurence of adverse events grade 4 (life threatening or disabling) according to National Cancer Institute Common Toxicity Criteria (CTC), version 3.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Myeloma</condition>
  <arm_group>
    <arm_group_label>No Bortezomib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 1: Melphalan 100 mg/m^2 intravenous (IV) days -4,-3 + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bortezomib 1.0 mg/m^2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 2: Bortezomib (Level 1) 1.0 mg/m^2 IV push on Days -9, -6, and -3, Melphalan 100 mg/m^2 IV days -4,-3 + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bortezomib 1.5 mg/m^2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 3: Bortezomib (Level 2) 1.5 mg/m^2 IV push on Days -9, -6, and -3, Melphalan + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trisenox (Arsenic Trioxide)</intervention_name>
    <description>0.25 mg/kg by vein over 2 hours, once a day for 7 days (Days -9 to -3).</description>
    <arm_group_label>Bortezomib 1.0 mg/m^2</arm_group_label>
    <arm_group_label>Bortezomib 1.5 mg/m^2</arm_group_label>
    <arm_group_label>No Bortezomib</arm_group_label>
    <other_name>ATO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Velcade (Bortezomib)</intervention_name>
    <description>Arm 1 (Level 1):&#xD;
1.0 mg/m^2 intravenous (IV) push on Days -9, -6, and -3. An IV push takes a short period of time (less than 1 minute).&#xD;
Arm 2 (Level 2):&#xD;
1.5 mg/m^2 intravenous (IV) push on Days -9, -6, and -3. An IV push takes a short period of time (less than 1 minute).</description>
    <arm_group_label>Bortezomib 1.0 mg/m^2</arm_group_label>
    <arm_group_label>Bortezomib 1.5 mg/m^2</arm_group_label>
    <other_name>PDP-341</other_name>
    <other_name>MLN341</other_name>
    <other_name>PS-341</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>100 mg/m2 by vein days -4,-3, over 30 minutes</description>
    <arm_group_label>Bortezomib 1.0 mg/m^2</arm_group_label>
    <arm_group_label>Bortezomib 1.5 mg/m^2</arm_group_label>
    <arm_group_label>No Bortezomib</arm_group_label>
    <other_name>Alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin C (Ascorbic Acid)</intervention_name>
    <description>1000 mg once a day through the vein for 7 days.</description>
    <arm_group_label>Bortezomib 1.0 mg/m^2</arm_group_label>
    <arm_group_label>Bortezomib 1.5 mg/m^2</arm_group_label>
    <arm_group_label>No Bortezomib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. a) Primary Refractory Disease (defined as failure to achieve even a partial response&#xD;
             to induction therapy) b) Consolidation of a partial remission (defined as a decrease&#xD;
             but continued presence of monoclonal protein on serum and urine immunofixation&#xD;
             electrophoresis, and/or the presence of plasmacytosis on bone marrow aspirate and&#xD;
             biopsy) c) Relapsing after prior therapy (disease relapsing after achieving a partial&#xD;
             or complete response to prior conventional or high-dose therapy).&#xD;
&#xD;
          2. Age up to 75 years.&#xD;
&#xD;
          3. Zubrod performance status of &lt;2.&#xD;
&#xD;
          4. Left ventricular ejection fraction &gt;40%. No uncontrolled arrhythmias or symptomatic&#xD;
             cardiac disease.&#xD;
&#xD;
          5. Forced expiratory volume (FEV1), forced volume vital capacity (FVC) and Diffusing&#xD;
             Capacity of the Lung for Carbon Monoxide (DLCO) &gt;40%. No symptomatic pulmonary&#xD;
             disease.&#xD;
&#xD;
          6. Serum bilirubin &lt;2 times upper limit of normal, alanine aminotransferase/SGPT &lt;4 times&#xD;
             upper limit of normal. No evidence of chronic active hepatitis or cirrhosis. No&#xD;
             effusion or ascites &gt;1L prior to drainage.&#xD;
&#xD;
          7. HIV-negative.&#xD;
&#xD;
          8. Negative Beta human chorionic gonadotrophin (hCG) test in a woman with child bearing&#xD;
             potential, defined as not post-menopausal for 12 months or no previous surgical&#xD;
             sterilization&#xD;
&#xD;
          9. Patient or guardian able to sign informed consent&#xD;
&#xD;
         10. Corrected QT interval less than 470 msec.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Corrected QT interval greater than 470 msec.&#xD;
&#xD;
          2. Patients in complete remission (defined as the absence of monoclonal protein on serum&#xD;
             and urine immunofixation electrophoresis, and the absence of plasmacytosis in bone&#xD;
             marrow aspirate and biopsy).&#xD;
&#xD;
          3. Patients with non-secretory myeloma.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muzaffar H. Qazilbash, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center website</description>
  </link>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 3, 2007</study_first_submitted>
  <study_first_submitted_qc>May 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2007</study_first_posted>
  <results_first_submitted>March 23, 2010</results_first_submitted>
  <results_first_submitted_qc>March 22, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 25, 2011</results_first_posted>
  <last_update_submitted>September 1, 2020</last_update_submitted>
  <last_update_submitted_qc>September 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Melphalan</keyword>
  <keyword>Trisenox</keyword>
  <keyword>Arsenic Trioxide</keyword>
  <keyword>Ascorbic Acid</keyword>
  <keyword>Vitamin C</keyword>
  <keyword>Velcade</keyword>
  <keyword>Bortezomib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Arsenic Trioxide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period June 2006 to December 2008. All participants recruited at UT MD Anderson Cancer Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>No Bortezomib</title>
          <description>Melphalan 100 mg/m^2 intravenous (IV) days -4,-3 + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily</description>
        </group>
        <group group_id="P2">
          <title>Bortezomib 1.0 mg/m^2</title>
          <description>Bortezomib (Level 1) 1.0 mg/m^2 IV push on Days -9, -6, and -3, Melphalan 100 mg/m^2 IV days -4,-3 + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily</description>
        </group>
        <group group_id="P3">
          <title>Bortezomib 1.5 mg/m^2</title>
          <description>Bortezomib (Level 2) 1.5 mg/m^2 IV push on Days -9, -6, and -3, Melphalan + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>No Bortezomib</title>
          <description>Melphalan 100 mg/m^2 intravenous (IV) days -4,-3 + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily</description>
        </group>
        <group group_id="B2">
          <title>Bortezomib 1.0 mg/m^2</title>
          <description>Bortezomib (Level 1) 1.0 mg/m^2 IV push on Days -9, -6, and -3, Melphalan 100 mg/m^2 IV days -4,-3 + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily</description>
        </group>
        <group group_id="B3">
          <title>Bortezomib 1.5 mg/m^2</title>
          <description>Bortezomib (Level 2) 1.5 mg/m^2 IV push on Days -9, -6, and -3, Melphalan + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="20"/>
            <count group_id="B4" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" lower_limit="47" upper_limit="70"/>
                    <measurement group_id="B2" value="59" lower_limit="45" upper_limit="67"/>
                    <measurement group_id="B3" value="64" lower_limit="49" upper_limit="75"/>
                    <measurement group_id="B4" value="60" lower_limit="45" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Reaching Complete Response (CR)</title>
        <description>Number of participants with CR at Day 180 who had maintained CR for at minimum of 4 weeks, and who had: No monoclonal protein in urine/serum when analyzed by immunofixation electrophoresis; bone marrow normal by morphological examination with &lt;5% plasma cells, &lt;1% aneuploid light chain restricted population by flow cytometry for DNA/cIg; and, while healing of bony lesion is not required, no new lytic lesion should appear. Further compression fracture of spine not considered progressive disease.</description>
        <time_frame>Baseline through Day 180, with assessments at Day 90 and Day 180</time_frame>
        <population>Analysis was per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>No Bortezomib</title>
            <description>Melphalan 100 mg/m^2 intravenous (IV) days -4,-3 + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily</description>
          </group>
          <group group_id="O2">
            <title>Bortezomib 1.0 mg/m^2</title>
            <description>Bortezomib (Level 1) 1.0 mg/m^2 IV push on Days -9, -6, and -3, Melphalan 100 mg/m^2 IV days -4,-3 + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily</description>
          </group>
          <group group_id="O3">
            <title>Bortezomib 1.5 mg/m^2</title>
            <description>Bortezomib (Level 2) 1.5 mg/m^2 IV push on Days -9, -6, and -3, Melphalan + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Reaching Complete Response (CR)</title>
          <description>Number of participants with CR at Day 180 who had maintained CR for at minimum of 4 weeks, and who had: No monoclonal protein in urine/serum when analyzed by immunofixation electrophoresis; bone marrow normal by morphological examination with &lt;5% plasma cells, &lt;1% aneuploid light chain restricted population by flow cytometry for DNA/cIg; and, while healing of bony lesion is not required, no new lytic lesion should appear. Further compression fracture of spine not considered progressive disease.</description>
          <population>Analysis was per protocol.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Toxicity</title>
        <description>The time to patient toxicity of drug combination bortezomib with arsenic trioxide, ascorbic acid and high-dose melphalan defined in days from baseline measure to occurence of adverse events grade 4 (life threatening or disabling) according to National Cancer Institute Common Toxicity Criteria (CTC), version 3.</description>
        <time_frame>Baseline to event occurence (assessed weekly first 30 days)</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Study period 2 years.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>No Bortezomib</title>
          <description>Melphalan 100 mg/m^2 intravenous (IV) days -4,-3 + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily</description>
        </group>
        <group group_id="E2">
          <title>Bortezomib 1.0 mg/m^2</title>
          <description>Bortezomib (Level 1) 1.0 mg/m^2 IV push on Days -9, -6, and -3, Melphalan 100 mg/m^2 IV days -4,-3 + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily</description>
        </group>
        <group group_id="E3">
          <title>Bortezomib 1.5 mg/m^2</title>
          <description>Bortezomib (Level 2) 1.5 mg/m^2 IV push on Days -9, -6, and -3, Melphalan + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ventriculat tachycardia/hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>small bowel obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>pneumonitis/death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>acute renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>pulmonary embolus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>mucositis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>low back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>elevated transaminases</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>hydronephrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>pulmonary edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Muzaffar H. Qazilbash, MD/Professor, Stem Cell Transplantation</name_or_title>
      <organization>University of Texas M.D. Anderson Cancer Center</organization>
      <phone>713-745-3458</phone>
      <email>mqazilba@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

